Side-by-side · Research reference
SemaglutidevsVIP
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedFlagship15/53 cited
BPhase 3HUMAN-REVIEWED9/42 cited
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
VIP
Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)
IV infusion · Inhaled (investigational)Brown 2023Boesing 2022
01Mechanism of Action
Parameter
Semaglutide
VIP
Primary target
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025
Pathway
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection
Downstream effect
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration
Feedback intact?
Glucose-dependent insulin release preserves physiological feedback
Yes — exogenous VIP acts as physiological agonist
Origin
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP
Antibody development
—
—
02Dosage Protocols
Parameter
Semaglutide
VIP
Standard dose (weight, Wegovy)
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
—
Frequency
Once weekly, same day each week
—
Titration schedule
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
—
Evidence basis
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Phase 3 RCT (TESICO)Brown 2023
816-patient randomized controlled trial in COVID-19 ARDS.
Duration
Indefinite for chronic indication
Discontinuation results in weight regain.
—
Reconstitution
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Lyophilized powder reconstituted with sterile diluent per protocol
Timing
Any time of day, with or without food
—
Half-life
~7 days (168 h)WEGOVY (semaglutide) injection 2021
~2 minutes (plasma)
Rapid clearance necessitates continuous infusion.
Intravenous (ARDS protocol)
—
60–90 mcg/kg/day via continuous infusion
TESICO trial protocol for COVID-19 ARDS.
Inhaled (investigational)
—
Variable dosing under clinical trial protocolsBoesing 2022
Delivered via nebulizer for direct pulmonary deposition.
Treatment duration
—
3–14 days (acute ARDS)
04Side Effects & Safety
Parameter
Semaglutide
VIP
GI symptoms
Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021
Nausea, diarrhea (VIP is endogenous GI peptide)
Injection site reaction
Mild erythema, pruritus
—
Thyroid C-cell tumours
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
—
Hypoglycemia
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
—
Gallbladder events
Increased cholelithiasis
—
Heart rate
Modest ↑ resting HR (~2-4 bpm)
—
Hypotension
—
Transient vasodilation-related blood pressure drop
Tachycardia
—
Reflex tachycardia secondary to vasodilation
Infusion site reactions
—
Erythema, phlebitis (IV administration)
Overall tolerability
—
Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo
Absolute Contraindications
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
VIP
- ·Known hypersensitivity to aviptadil or formulation components
Relative Contraindications
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
VIP
- ·Severe hypotension or shock states (monitor blood pressure)
- ·Pregnancy — insufficient safety data
05Administration Protocol
Parameter
Semaglutide
VIP
1. Reconstitution / device
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).
3. Timing
Once weekly, same day. Day can be changed if ≥2 days separate doses.
Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.
4. Storage
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.
5. Needle
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.
06Stack Synergy
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)
VIP
— no documented stacks